Why people with prior SARS-CoV-2 infection still need to be vaccinated
Since vaccine shortage is expected to last at least for a few months, it may seem appealing to delay or avoid vaccinating those who have been naturally infected. But does…
A Science and Technology Blog
Since vaccine shortage is expected to last at least for a few months, it may seem appealing to delay or avoid vaccinating those who have been naturally infected. But does…
With the virus running amok in the country and vaccines in short-supply, the U.K. is attempting an untested strategy of delaying the second dose of both AstraZeneca and Pfizer vaccine even in the absence of data from large trials. The intent is to rapidly but partially protect more individuals who are at risk.
Unlike in other groups, national databases of people with comorbidities are not available. However, though not comprehensive, since 2010, State governments have been conducting population-based district level screening to detect…
Meanwhile, the Indian government has spelt out four high-risk groups — healthcare workers, frontline workers, those over 50 years of age and those aged below 50 years but with co-morbidities…
The greatly reassuring decision to seek additional safety and immunogenicity data from the Pune-based Serum Institute of India and Hyderabad’s Bharat Biotech underlines the regulator’s priorities even for emergency use…
Unlike Pfizer, AstraZeneca, which is carrying out the phase-3 trials of the Oxford vaccine in four countries, is yet to secure a nod from any of the regulatory agencies despite…
Two doses of the vaccine given in two different regimen showed different efficacies. In the case of the regimen (involving 2,741 participants) where a halved dose was used as a…
The results of the Phase-1 trial, announced in August, first through a press release and then through a preprint a week later, showed that the vaccine induced neutralising antibodies and…